Dendritic cells vaccinations are increasingly used in order to develop antitumoral immune response. This will be a Phase 2 trial using autologous dendritic cells pulsed with leukemic apoptotic corpse in acute myelogenous leukemia (AML) patients in first or second Complete remission (CR).

Inclusion Criteria:

• Age ≥ 60 years
• Informed consent signed
• Serology HIV, hepatitis B, hepatitis C, HTLV 1 and 2 and Syphilis always negative (new achievement tests)
• Performance Statute <=2
• Must not be eligible for allogeneic transplantation
• No progressive disease
• Bone marrow and/or peripheral blasts >50% before chemotherapyBlasts >=2.4 10*8 (collected prior to chemotherapy) available No contraindication to cytapheresis
• AML in CR2, except M3-AML
• Patients with refractory AML after induction treatment and a patient eligible for salvage treatment may allow the production of a first complete remission.
• Patient with newly diagnosed AML with unfavorable cytogenetics and for whom (which) a course of intensive induction and consolidation treatment for outpatients are possible
• Patient with newly diagnosed AML with a non-adverse cytogenetics AND either refused to participate in the protocol GOELAMS LAMS-2007, against the exclusion criteria, indicating participation in the protocol GOELAMS LAMS-2007 and for whom (which) a course of induction and intensive out patient treatment for consolidation are possible
• Absence of donor HLA-compatible family or non-family and absence of placental blood available for performing an allograft.

Exclusion Criteria

• Patients who, for reasons psychological, social or geographical boundaries, could be monitored during the study
• No infections or visceral (cardiac, lung, brain, ...) serious uncontrolled
• History of positive allogeneic bone marrow or solid organ transplantation.
• Previous history of autoimmune disease other than vitiligo
• History of other cancer, except cervical carcinoma in situ or basal cell carcinoma of the skin unless deemed cured for over 5 years.
• Inability to collect at the diagnosis of relapsed AML, enough leukemic cells (> 2.4 x108)
• Inability to collect during remission, a sufficient number of monocytes in two leukapheresis maximum
• Failure to obtain a maturation of monocytes
• Patient with AML 3
• Patient may receive an allogeneic hematopoietic stem cell
• No treatment related to treatment of molecules in preclinical development underway or completed MA within the last 4 weeks